Simon Hitier

Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer

DJ Slamon, W. Eiermann, NJ Robert et al. · Cancer Research · 2016 · 149 citations

Medicine, Oncology, Pharmacology +17

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

Eric Van Cutsem, C. Boni, Josep Tabernero et al. · Annals of Oncology · 2014 · 133 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme

Axel Heidenreich, Sergio Bracarda, Malcolm D. Mason et al. · European Journal of Cancer · 2014 · 103 citations · Full text

Medicine, Oncology, Pharmacology +13

Refined approximations to permutation tests for multivariate inference

Frédérique Kazi-Aoual, Simon Hitier, Robert Sabatier et al. · Computational Statistics & Data Analysis · 1995 · 86 citations

Natural Sciences, Biostatistics, Statistics +11

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

John R. Mackey, Tadeusz Pieńkowski, John Crown et al. · Annals of Oncology · 2016 · 63 citations

Medicine, Oncology, Pharmacology +16